期刊
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
卷 23, 期 -, 页码 582-596出版社
CELL PRESS
DOI: 10.1016/j.omtm.2021.10.014
关键词
-
资金
- Singapore Ministry of Health's National Medical Research Council [NMRC/OFLCG/003/2018, MOH-000465-01]
- Agency for Science, Technology and Research, Singapore [IAF-PP:H19/01/a0/022]
Significant progress has been made in adoptive transfer of CAR-modified NK cells for treating relapsed or refractory AML. The co-expression of NKG2D CAR and IL-15 in NK cells enhances anti-leukemic activity and offers a promising approach for AML therapy.
Promising progress has been made in adoptive transfer of allogeneic natural killer (NK) cells to treat relapsed or refractory acute myeloid leukemia (AML). In this regard, chimeric antigen receptor (CAR)-modification of NK cells is considered as a compelling approach to augment the specificity and cytotoxicity of NK cells against AML. Using a non-viral piggyBac transposon technology and human peripheral blood-derived primary NK cells, we generated CAR-NK cells to target NKG2D ligands and demonstrated their in vitro activity in lysing cancer cells expressing the ligands and in vivo efficacy in inhibiting tumor growth in a xenograft KG-1 AML model. We further generated CAR-NK cells co-expressing transgenes for the NKG2D CAR and interleukin-15 (IL-15). The ectopic expression of IL-15 improved the in vitro and in vivo persistence of NKG2D CAR-NK cells, leading to enhanced in vivo tumor control and significant prolongation of mouse survival in the KG-1 AML model. Collectively, our findings demonstrate the ectopic expression of IL-15 as an important means to improve the antileukemic activity of NKG2D CAR-NK cells. Our study further illustrates the feasibility of using the piggyBac non-viral platform as an efficient and cost-effective way for CAR-NK cell manufacturing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据